quinta-feira, abril 28, 2005
Atrasos com nova combinação da Gilead e BMS
Gilead Sciences on Tuesday said an experimental pill combining its HIV treatment Truvada with Bristol-Myers Squibb Co's popular Sustiva treatment will be scrapped, but that a second version of the pill will be developed and could be submitted to US regulators for approval by year's end.
Gilead, a biotechnology company based in Foster City, California, already sells Truvada - a once-daily product which is itself a combination of the company's HIV treatments Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Gilead and Bristol-Myers agreed last year to to develop a once-daily pill containing their respective medicines.
But Gilead said the first formulation of the new product created bloodstream levels of Sustiva (efavirenz) that were lower than those typically seen with the recommended 600 milligram dose of Sustiva used alone. Gilead said if the second formulation of the new product produces satisfactory bloodstream levels of its drugs and Sustiva, the companies could seek US approval for it by the end of the year.
(...)
Gilead, a biotechnology company based in Foster City, California, already sells Truvada - a once-daily product which is itself a combination of the company's HIV treatments Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Gilead and Bristol-Myers agreed last year to to develop a once-daily pill containing their respective medicines.
But Gilead said the first formulation of the new product created bloodstream levels of Sustiva (efavirenz) that were lower than those typically seen with the recommended 600 milligram dose of Sustiva used alone. Gilead said if the second formulation of the new product produces satisfactory bloodstream levels of its drugs and Sustiva, the companies could seek US approval for it by the end of the year.
(...)
